Value-Added Specialist Hyloris Launches IPO
Proceeds Will Allow Firm To Focus On US 505(b)(2) Opportunities
Value-added medicines specialist Hyloris Pharmaceuticals is launching an IPO to provide the funds it needs to focus on opportunities through the US 505(b)(2) pathway.
You may also be interested in...
Belgian value-added medicines specialist Hyloris Pharmaceuticals has bolstered its management team with the appointment of a chief operating officer, shortly after receiving eight European approvals for its Maxigesic IV pain treatment.
With the main aim of developing its existing product portfolio and pursuing business development opportunities in the US, Hyloris Pharmaceuticals has successfully raised €80m through a public listing. The company has announced its financial results for the first half of 2020.
Fresh from a successful IPO, Belgian value-added medicines specialist Hyloris Pharmaceuticals has the financial firepower it needs to pursue ambitious expansion plans that include building out a US commercial infrastructure, CEO Stijn Van Rompay tells Generics Bulletin in an exclusive interview.